Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.

Also called NCT05373680

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 118 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05373680
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05373680. Randomized; no masking; primary purpose treatment. Start 2022-01-01 (actual); primary completion 2024-04-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression
Condition
Renal Insufficiency, Chronic
Intervention (Drug)
Metformin
Intervention (Drug)
Empagliflozin
Intervention (Other)
Control
Lead sponsor
Tanta University (class: other)
Collaborator
Mansoura University (class: other)

Record details

Record id
cardio:ct-nct05373680
Content hash
4e9ad1a9e227c4c1997b40c3bbec42625cf035eecf72370f802fa3bd8107f1a1